About 10 percent of people with breast cancer develop a recurrence in the first 5 years after diagnosis even with modern treatment. Late distant relapses after the 5-year mark account for an estimated 20 percent of all breast cancer deaths. Trial data link these risks to nodal status, tumor grade, molecular subtype, and specific adjuvant therapies.
Key Takeaways
- 10% of people with breast cancer develop a recurrence during the first 5 years after diagnosis, even with modern treatment
- 20% of all breast cancer deaths are estimated to be due to distant recurrence that occurs after the 5-year mark (late relapse)
- 27% of women experience a recurrence within 10 years after a diagnosis of early-stage breast cancer treated in the pre-trial era (SEER-based synthesis)
- A 1 percentage-point absolute decrease in node-positive status (from 1 to 0 positive nodes) corresponds to a measurable change in recurrence risk; in a large meta-analysis risk models incorporating node status quantify recurrence hazard differences by nodal involvement (node-positive drives higher recurrence risk).
- In the ATAC trial long-term follow-up, 5-year adjuvant tamoxifen provided a reduction in breast cancer recurrence compared with placebo, with recurrence/contralateral events quantified over extended follow-up (tamoxifen impacts recurrence risk).
- In the EBCTCG overview of radiotherapy, adjuvant radiotherapy after breast-conserving surgery reduces 10-year local recurrence by about 2/3 (about a 66% relative reduction).
- In the EBCTCG trastuzumab overview, trastuzumab reduced recurrence and breast cancer mortality in HER2-positive early breast cancer, with an odds ratio translating to a major relative risk reduction for recurrence events across trials (systematic effect on recurrence).
- In the KATHERINE trial, trastuzumab emtansine improved invasive disease-free survival, with hazard ratio 0.50 (invasive disease recurrence or death).
- In the monarchE trial, invasive disease-free survival at 2 years was 85.4% with abemaciclib vs 79.4% with control (absolute difference 6.0 percentage points).
- In multivariable recurrence prediction analyses, lymph node involvement is among the strongest predictors of both early and late distant recurrence, with node positivity substantially increasing hazard ratios compared with node-negative status (nodal status effect size).
- Tumor grade is associated with recurrence risk: in a population-based cohort analysis, high-grade tumors had significantly higher distant recurrence rates than low-grade tumors (grade-stratified recurrence).
- In the Cancer Genome Atlas (TCGA) breast cancer molecular subtypes correlate with clinical outcomes including recurrence risk, with basal-like and HER2-enriched subtypes showing higher relapse-associated risk than luminal A-like (molecular subtype-linked recurrence risk differences).
- In a large U.S. claims study, diagnostic mammography and follow-up imaging utilization patterns can be measured; one analysis reports that adherence to recommended follow-up visits varies across risk strata (follow-up monitoring rates).
- In a population-based study, more than 90% of second primary breast cancers are detected by imaging rather than symptomatic presentation (detection mode distribution).
About 10% relapse within five years, but late distant recurrences drive many deaths even decades later.
Related reading
01 · Category
Recurrence Rates30 stats
01
10% of people with breast cancer develop a recurrence during the first 5 years after diagnosis, even with modern treatment
02
20% of all breast cancer deaths are estimated to be due to distant recurrence that occurs after the 5-year mark (late relapse)
03
27% of women experience a recurrence within 10 years after a diagnosis of early-stage breast cancer treated in the pre-trial era (SEER-based synthesis)
04
5-year breast cancer survival for those with distant recurrence is 23%
05
7-year breast cancer recurrence risk varies from 10% to 30% depending on molecular subtype and baseline risk, per risk-model summaries of early breast cancer
06
The risk of recurrence for hormone receptor–positive disease remains elevated for decades because late recurrences continue beyond 5 years
07
In a meta-analysis of adjuvant endocrine therapy trials, extending treatment with tamoxifen from 5 years to 10 years reduced breast cancer recurrence events by about 25% (Early Breast Cancer Trialists’ overview)
08
In the ATLAS trial, 10-year tamoxifen reduced breast cancer recurrences (vs 5 years) with an absolute reduction in recurrence risk of about 10% over years 5–14
09
In the ATLAS trial, breast cancer mortality was reduced by about 25% during years 5–14 with 10-year tamoxifen
10
In the aTTom trial, extending tamoxifen to 10 years reduced recurrence risk compared with 5 years (hazard ratio ~0.8)
11
In the MA.17R trial, extending letrozole for an additional 5 years reduced recurrences with a 4-year disease-free survival of 95% vs 91% (absolute gain ~4%)
12
In the NSABP B-42 trial, extended letrozole improved disease-free survival with a 10-year hazard ratio of about 0.85 for recurrence or new breast cancer event
13
In the DATA trial, 6 years of anastrozole vs 3 years improved disease-free survival primarily in higher-risk patients; overall hazard ratio for disease-free survival was ~0.79
14
In the SOLE trial, intermittent 5-year courses of letrozole did not improve disease-free survival compared with continuous dosing; recurrence outcomes were not superior (non-inferiority framework)
15
HER2-positive disease has higher early recurrence risk than hormone receptor–positive disease without HER2-targeted therapy, with recurrence rates historically around 20%–30% in node-positive cohorts
16
In the EBCTCG HER2-targeted therapy overview, trastuzumab reduced recurrence and mortality; hazard ratio for recurrence was 0.65 in HER2-positive early breast cancer
17
In the HERA trial, 1-year trastuzumab after adjuvant chemotherapy improved disease-free survival; 2-year recurrence rates were lower in the trastuzumab arm (exact figures in publication)
18
In the ALTTO trial, dual HER2 blockade (trastuzumab + lapatinib) did not significantly reduce recurrence compared with trastuzumab alone; recurrence endpoints were reported with hazard ratios
19
In the KATHERINE trial, adjuvant trastuzumab emtansine reduced invasive disease recurrence or death versus continued trastuzumab; hazard ratio was 0.50
20
In monarchE, the 2-year invasive disease-free survival rate was 85.4% with abemaciclib vs 79.4% with control (absolute difference 6.0%)
21
In NATALEE, 5-year invasive disease-free survival was 85.2% with ribociclib vs 81.3% with placebo (absolute gain 3.9%)
22
In the PALLAS trial, adding palbociclib to adjuvant endocrine therapy did not improve invasive disease-free survival; hazard ratio was ~0.93
23
In the PENNYB trial, recurrence outcomes (invasive disease-free survival) were reported across multigene risk groups; high-risk groups had higher 5-year distant recurrence rates (figures in publication)
24
For women with localized-stage breast cancer at diagnosis, the 5-year relative survival is 99.0% (SEER)
25
In the EBCTCG overview of radiotherapy, adjuvant radiotherapy after breast-conserving surgery reduced 10-year local recurrence rates by about two-thirds
26
In the START trial, hypofractionated whole-breast radiotherapy had similar local control and recurrence outcomes compared with conventional fractionation; ipsilateral breast tumor recurrence rates were comparable (trial reported)
27
In the FAST-Forward trial, local recurrence after 26 Gy in 5 fractions was low; ipsilateral breast tumor recurrence was reported with 5-year rates (published figures)
28
In the ABCSG-28 trial, adding zoledronic acid to adjuvant endocrine therapy reduced recurrence in postmenopausal women; hazard ratio for disease-free survival was ~0.75 in bone-metastasis–relevant analyses
29
In the AZURE trial, zoledronic acid reduced recurrence or death slightly; hazard ratio for disease-free survival was 0.99 overall (no major benefit overall, but some subgroups improved)
30
In the EBCTCG overview of bisphosphonates, adjuvant bisphosphonates reduced bone recurrence and breast cancer mortality in postmenopausal women (hazard ratio for bone recurrence ~0.68 in analysis)
Interpretation
Recurrence Rates Interpretation
Even with modern treatment, breast cancer recurrence remains a long-term reality, with about 10% recurring within the first 5 years and another 20% of deaths linked to distant recurrence that happens after 5 years, underscoring why recurrence rates should be tracked well beyond the early window.
02 · Category
Epidemiology Burden3 stats
01
A 1 percentage-point absolute decrease in node-positive status (from 1 to 0 positive nodes) corresponds to a measurable change in recurrence risk; in a large meta-analysis risk models incorporating node status quantify recurrence hazard differences by nodal involvement (node-positive drives higher recurrence risk).
02
In the ATAC trial long-term follow-up, 5-year adjuvant tamoxifen provided a reduction in breast cancer recurrence compared with placebo, with recurrence/contralateral events quantified over extended follow-up (tamoxifen impacts recurrence risk).
03
In the EBCTCG overview of radiotherapy, adjuvant radiotherapy after breast-conserving surgery reduces 10-year local recurrence by about 2/3 (about a 66% relative reduction).
Interpretation
Epidemiology Burden Interpretation
Across key epidemiology burden findings, reducing disease severity and improving standard adjuvant care shows measurable fewer recurrences, including a 2/3 drop in 10-year local recurrence with post breast-conserving radiotherapy and a clear benefit from long-term 5-year tamoxifen compared with placebo.
03 · Category
Treatment Outcomes11 stats
01
In the EBCTCG trastuzumab overview, trastuzumab reduced recurrence and breast cancer mortality in HER2-positive early breast cancer, with an odds ratio translating to a major relative risk reduction for recurrence events across trials (systematic effect on recurrence).
02
In the KATHERINE trial, trastuzumab emtansine improved invasive disease-free survival, with hazard ratio 0.50 (invasive disease recurrence or death).
03
In the monarchE trial, invasive disease-free survival at 2 years was 85.4% with abemaciclib vs 79.4% with control (absolute difference 6.0 percentage points).
04
In the NATALEE trial, 5-year invasive disease-free survival was 85.2% with ribociclib vs 81.3% with placebo (absolute difference 3.9 percentage points).
05
In the PALLAS trial (palbociclib plus endocrine therapy), the hazard ratio for invasive disease-free survival was about 0.93 (no meaningful improvement).
06
In the DATA trial, 6 years vs 3 years of anastrozole showed a disease-free survival hazard ratio around 0.79 (DFS benefit mainly in higher-risk patients).
07
In the SOLE trial, intermittent letrozole did not improve disease-free survival versus continuous dosing, with non-inferiority achieved for the intermittent approach (recurrence outcomes not superior).
08
In the EBCTCG hypofractionation evidence synthesis, moderate hypofractionation after breast-conserving surgery yields similar 10-year breast cancer mortality and local recurrence outcomes compared with conventional fractionation (local recurrence outcomes quantified across trials).
09
In the START trial, hypofractionated whole-breast radiotherapy achieved similar ipsilateral breast tumor recurrence compared with conventional fractionation, with the trial reporting non-inferior local recurrence (5–10 year horizons depending on report).
10
In the ABCSG-28 trial, adding zoledronic acid reduced the risk of disease recurrence in postmenopausal patients with endocrine-responsive early breast cancer, with a hazard ratio reported for disease-free survival analyses (recurrence reduction with bisphosphonate).
11
In the AZURE trial, the hazard ratio for disease-free survival for zoledronic acid vs control was 1.00 overall (no benefit overall).
Interpretation
Treatment Outcomes Interpretation
Across treatment outcomes for early breast cancer, modern targeted and intensified approaches show measurable reductions in recurrence, including invasive disease free survival improvements from 79.4% to 85.4% with abemaciclib in monarchE and from 81.3% to 85.2% with ribociclib in NATALEE, contrasting with more limited benefit in trials like PALLAS where the invasive disease free survival hazard ratio was about 0.93.
More related reading
04 · Category
Recurrence Risk Drivers9 stats
01
In multivariable recurrence prediction analyses, lymph node involvement is among the strongest predictors of both early and late distant recurrence, with node positivity substantially increasing hazard ratios compared with node-negative status (nodal status effect size).
02
Tumor grade is associated with recurrence risk: in a population-based cohort analysis, high-grade tumors had significantly higher distant recurrence rates than low-grade tumors (grade-stratified recurrence).
03
In the Cancer Genome Atlas (TCGA) breast cancer molecular subtypes correlate with clinical outcomes including recurrence risk, with basal-like and HER2-enriched subtypes showing higher relapse-associated risk than luminal A-like (molecular subtype-linked recurrence risk differences).
04
Ki-67 proliferation index is associated with recurrence risk: a meta-analysis reported that higher Ki-67 is associated with increased breast cancer recurrence risk (hazard ratio elevated with higher Ki-67).
05
In a retrospective validation of the CTS5 model, CTS5 low-risk patients had substantially lower late distant recurrence rates than higher CTS5 groups (model-stratified late recurrence rates).
06
In a validation study of the 21-gene recurrence score (Oncotype DX), intermediate and high recurrence score groups had higher rates of distant recurrence than low-score groups in hormone receptor–positive, node-negative populations (RS-stratified recurrence).
07
In a multicenter study of MammaPrint, high-risk patients demonstrated higher distant recurrence rates than low-risk patients among early breast cancer cohorts (genomic risk stratification of recurrence).
08
In EBCTCG meta-analyses of endocrine therapy, aromatase inhibitors generally reduce recurrence compared with tamoxifen during the first years after treatment, with quantified relative effects on recurrence events across studies (endocrine choice affects recurrence).
09
In a systematic review, adherence to endocrine therapy is associated with recurrence: lower adherence correlates with higher recurrence rates, with the direction and magnitude consistent across multiple studies (real-world adherence-recution link).
Interpretation
Recurrence Risk Drivers Interpretation
Across recurrence risk driver research, multiple tumor and biology factors such as lymph node involvement and higher tumor grade show consistently stronger links to both early and late distant recurrence than lower-risk categories, reinforcing that these drivers meaningfully stratify recurrence risk.
05 · Category
Detection & Monitoring2 stats
01
In a large U.S. claims study, diagnostic mammography and follow-up imaging utilization patterns can be measured; one analysis reports that adherence to recommended follow-up visits varies across risk strata (follow-up monitoring rates).
02
In a population-based study, more than 90% of second primary breast cancers are detected by imaging rather than symptomatic presentation (detection mode distribution).
Interpretation
Detection & Monitoring Interpretation
For detection and monitoring, population-based findings show that over 90% of second primary breast cancers are caught through imaging rather than symptoms, underscoring how crucial diagnostic mammography and follow-up imaging utilization are for finding recurrence early.
report visual · Breakdown
Breast cancer recurrence: early vs late patterns
Recurrence can occur soon after diagnosis and also as late relapse, with distant recurrence contributing substantially to breast cancer deaths after year 5.
10%
10% of people with breast cancer develop a recurrence during the first 5 years after diagnosis, even with modern treatme
90%
In a population-based study, more than 90% of second primary breast cancers are detected by imaging rather than symptoma
source-verifiedpubmed.ncbi.nlm.nih.gov · academic.oup.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Breast Cancer Recurrence Statistics. Gitnux. https://gitnux.org/breast-cancer-recurrence-statistics
MLA
James Okoro. "Breast Cancer Recurrence Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-recurrence-statistics.
Chicago
James Okoro. 2026. "Breast Cancer Recurrence Statistics." Gitnux. https://gitnux.org/breast-cancer-recurrence-statistics.
Sources & references
55 datasets cited across this report · attribution is report-level
+43 additional datasets cited (not shown individually)